About Merus Labs
Merus Labs is a Healthcare company based in Toronto (Canada) founded in 2009, and was acquired by Norgine in May 2017. It operates as a pharmaceuticals for womens health, cancer, infectious and cardiovascular disease. Its focus areas include Diversified Pharmaceuticals.
Company details
Merus Labs was established in 2009 in Toronto, Canada, within the pharmaceuticals sector. Corporate growth is pursued through an opportunistic product acquisition strategy. The portfolio encompasses Sintrom for thromboembolic conditions, Enablex for overactive bladder, Salagen for radiation-induced dry mouth, and Vancocin capsules for bacterial infections like C. difficile. Operations focus on sourcing and integrating these treatments for womens health, cancer, infectious, and cardiovascular areas.
- Headquarters Toronto, Canada
- Stage Acquired
- SectorsHealthcare
- Website meruslabs.com
- Social LinkedIn
- Acquired by Norgine (May 2017)
Funding Insights of Merus Labs
- Total Rounds 6
- Last Round Post-IPO — $20M
- First Round $2.1M
(Mar 2011)
- Investors Count 2
All 6 funding rounds of Merus Labs with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2016 | $20M | Post-IPO | – | – | – |
| Apr 2015 | $60M | Post-IPO | – | – | – |
| Mar 2014 | $20M | Post-IPO | – | – | – |
| Jun 2013 | $4.61M | Post-IPO | – | – | – |
| Jul 2012 | $55M | Debt – Conventional | – | – | |
| Mar 2011 | $2.1M | Post-IPO | – | – |
3 investors in total: 3 institutional.
Investors in Merus Labs
Merus Labs has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Norgine, PDL BioPharma and PowerOne Capital Markets.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biopharmaceutical company undergoing dissolution and asset distribution processes. | – | pdl.com | - | |
- | – | poweronecapital.com | - | |
Proprietary therapeutic products for gastrointestinal diseases are developed and marketed. | 1906 | norgine.com | Amsterdam, Netherlands |
Investor details for Merus Labs
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Merus Labs
5 dated milestones of Merus Labs across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Merus Labs is founded.
- Funding First funding round of $2.1M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $20.0M.
- Exit Acquired by Norgine.
Top companies in Pharmaceuticals & Distribution
10 companies that operate in the same segment as Merus Labs (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Merus Labs
Complete news archive for Merus Labs
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Merus Labs
Merus Labs was founded in 2009 and raised its 1st funding round 2 years after it was founded.
Merus Labs is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Merus Labs was established in 2009 in Toronto, Canada, within the pharmaceuticals sector. Corporate growth is pursued through an opportunistic product acquisition strategy. The portfolio encompasses Sintrom for thromboembolic conditions, Enablex for overactive bladder, Salagen for radiation-induced dry mouth, and Vancocin capsules for bacterial infections like C. difficile. Operations focus on sourcing and integrating these treatments for womens health, cancer, infectious, and cardiovascular areas.
Merus Labs has 3 investors. Key investors include Norgine, PDL BioPharma, and PowerOne Capital Markets.
Yes. Merus Labs was acquired by Norgine in May 2017.